Aflac AFL has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 2 | 3 | 0 | 1 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 1 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.17, a high estimate of $95.00, and a low estimate of $75.00. This upward trend is apparent, with the current average reflecting a 4.99% increase from the previous average price target of $80.17.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Aflac. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| John Barnidge | Piper Sandler | Raises | Overweight | $95.00 | $90.00 |
| Nigel Dally | Morgan Stanley | Lowers | Equal-Weight | $80.00 | $85.00 |
| Elyse Greenspan | Wells Fargo | Raises | Equal-Weight | $83.00 | $82.00 |
| Wilma Burdis | Raymond James | Raises | Outperform | $88.00 | $83.00 |
| Brian Meredith | UBS | Raises | Neutral | $84.00 | $80.00 |
| Alex Scott | Goldman Sachs | Raises | Sell | $75.00 | $61.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Aflac. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aflac compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Aflac's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Aflac's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Aflac analyst ratings.
About Aflac
Aflac Inc offers supplemental health insurance and life insurance in United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling majority of its policies directly to consumers at their places of work and also reaches out to its customers out of their worksite through digital mediums. The company has two reportable business segments; Aflac Japan which generates the majority of the revenue, and Aflac U.S.
A Deep Dive into Aflac's Financials
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Aflac's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -2.5%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Aflac's net margin is impressive, surpassing industry averages. With a net margin of 6.95%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Aflac's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.2% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Aflac's ROA stands out, surpassing industry averages. With an impressive ROA of 0.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Aflac's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.33.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
